Science News

... from universities, journals, and other research organizations

Gene May Play A Pivotal Role In Developing Alcoholism

Oct. 25, 2006 — Gamma-aminobutyric acid (GABA) is the major inhibitory neurotransmitter in the brain. GABA has been implicated in the development of alcoholism, although the mechanisms through which this occurs are unclear. A recent "association" study has found that an enzyme called glutamate decarboxylase (GAD) -- which is involved in the synthesis of GABA -- may play a significant role.


Share This:

Results are published in the November issue of Alcoholism: Clinical & Experimental Research.

"GABA's main function is to inhibit excitatory neuro-activities so that the brain can remain stable," said Andrew T.A. Cheng, Distinguished Research Fellow and professor at Academia Sinica in Taipei. "When one consumes alcohol, GABA levels rise in the brain, providing sedative effects. When one drinks regularly, a counter mechanism is set up until gradually, the ability to raise GABA is reduced. Defects in GABA synthesis may push one to drink more alcohol in order to treat abnormal physiology caused by low GABA Furthermore, individuals who release GABA slowly during alcohol consumption may consume more alcohol to reach its sedative effects, exposing themselves to a higher risk of alcohol dependence." Cheng is also the corresponding author for the study.

"This study takes a so-called candidate gene approach to explore the possible role of GABA in the development of alcoholism," observed Wei-Jen Chen, director of the Institute of Epidemiology at the National Taiwan University Hospital. "GAD has two forms, encoded by the GAD1 and GAD2 genes that are located in different chromosomes, and is involved in the production of GABA from glutamate. This knowledge is mainly derived from studies on mice, whereas human studies so far point to the potential role of GAD in schizophrenia."

Researchers examined two groups of Han Taiwanese men recruited from community and clinical settings: 140 who met Diagnostic and Statistical Manual-III-R criteria for alcohol dependence (22 to 69 years of age); and 146 individuals without alcohol dependence (41 to 84 years of age).

"This is the first study reporting a significant association of the GAD1 gene with the development of alcoholism," said Cheng. "Because GAD1 is the major enzyme in the synthesis of GABA, GAD1 may act as a common factor in the development of common diseases across populations, including alcoholism."

"Although statistical analyses seem to indicate that certain genetic variants of the GAD1 gene were associated with alcohol dependence," added Chen, "the meaning of this association remains to be clarified. For example, one may guess that these genetic variants are probably merely markers that are closely located to a 'real' susceptibility gene for alcohol dependence and hence form 'linkage disequilibrium' with it. Nonetheless, this study does remind researchers that GAD might be involved in maintenance of GABA levels. People with a lower GABA level that is attributed to a less active form of GAD may have a greater chance to drink alcohol to help augment the effects of the inhibitory neurotransmission exerted by GABA. This may also help explain co-occurring anxiety disorders in people with alcohol dependence."

For example, said Chen, patients with schizophrenia are known to have an increased co-occurrence of substance use disorders. Given that the GAD gene has been implicated in genetic susceptibility to schizophrenia too ... "it might be that the GAD gene confers a common liability to both alcohol dependence and schizophrenia," he said, "probably via the dysfunction of the GABA-related neurotransmission."

Nonetheless, said Cheng, "in order to become an alcoholic, one must be exposed to alcohol first. An individual's genetic background may play a role in pushing someone to become an alcoholic by creating physical and psychological memories that lead to a further demand for alcohol. Our findings may provide a scientific basis to further explore GABA involvement in the development of alcoholism. Advances in this field are likely to create new treatment strategies in alcoholism, either by modern molecular intervention, traditional chemical therapeutics, or psychological approaches based on a GABA-deficit theory."

Alcoholism: Clinical & Experimental Research (ACER) is the official journal of the Research Society on Alcoholism and the International Society for Biomedical Research on Alcoholism. Co-authors of the ACER paper, "Glutamate decarboxylase genes and alcoholism in Han Taiwanese men," were: El-Wui Loh of the Division of Mental Health and Drug Abuse Research at the National Health Research Institutes in Taipei; Hsien-Yuan Lane of the Department of Psychiatry at the China Medical University Hospital in Taichung; and Pi-Shan Chang and Li-Wen Ku, Chien-Hsiun Chen and Kathy H.T. Wang of the Institute of Biomedical Sciences at Academia Sinica in Taipei. The study was funded by the National Science Council, and the Academia Sinica of Taipei.

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:

|

Story Source:

The above story is reprinted from materials provided by Alcoholism: Clinical & Experimental Research, via EurekAlert!, a service of AAAS.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.


APA

MLA

Note: If no author is given, the source is cited instead.

Search ScienceDaily

Number of stories in archives: 137,307

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily's archives for related news topics,
the latest news stories, reference articles, science videos, images, and books.

Recommend ScienceDaily on Facebook, Twitter, and Google:

Other social bookmarking and sharing services:

|

 
  more breaking science news

Social Networks


Recommend ScienceDaily on Facebook, Twitter, and Google +1:

Other social bookmarking and sharing tools:

|

Breaking News

... from NewsDaily.com

In Other News ...

Science Video News


Pill To Fight Alcoholism

Neuropharmacologists ran clinical trials to find that a drug called topiramate is an effective therapeutic medication for decreasing heavy drinking. ...  > full story

Strange Science News

 

Free Subscriptions

... from ScienceDaily

Get the latest science news with our free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Feedback

... we want to hear from you!

Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?

Post this page to your favorite social bookmarking site:
Include this item in your blog or web site:
Cite this article in your essay, paper, or report:
Email this page's link to a friend or colleague: